Investors and Media
     
     
  Events, Presentations and Webcasts
 
Press Releases
 
  Bionovo in the News
 
  Publications
 
  FAQ
 
  Stock Details
 
  Analyst Coverage
 
  SEC Filings
 
  SEC Filings - XBRL Content
 
  Corporate Governance
 
 

BIONOVO, INC.

$N/A (N/A)

BNVI.PK

Press Release

Back

Printer Friendly Version View printer-friendly version

Bionovo Announces First Quarter 2011 Highlights and Financial Results

EMERYVILLE, Calif., May 11, 2011 /PRNewswire/ -- Bionovo, Inc. (NASDAQ: BNVI) today announced first quarter highlights and financial results for the three months ended March 31, 2011.

"We started the first quarter by raising the necessary capital to advance Menerba, our lead drug for the treatment of menopausal hot flashes," said Isaac Cohen, O.M.D., Bionovo's Chairman and Chief Executive Officer. "We have since been proceeding with our clinical plan and manufacturing Menerba for the various clinical and non-clinical studies. As previously stated, we expect to be able to initiate the Phase 3 clinical trials for Menerba in the 3rd quarter of this year."

Key Events and Milestones

  • On February 2nd, the Company closed a follow-on stock offering, with net proceeds of $27.3 million. The financing was led by Roths-Invest Asset Management AG, from the Nathan Rothschild Group, Zurich, Switzerland, and was underwritten by Cowen and Company.
  • On March 28th, Bionovo announced that it had initiated a "Tolerability Trial" for Menerba, the Company's drug candidate for the treatment of menopausal hot flashes. The trial is intended to explore the tolerability of higher doses of Menerba.

"Our tolerability trial is progressing well, and at the anticipated rate. There have been no safety issues identified in the trial to date," said Dr. Mary Tagliaferri, Bionovo's President and Chief Medical Officer. "The data being gathered is as we forecasted, and we expect the trial will achieve its goals."

  • The Company has also initiated additional preclinical, repeat-dose, toxicology studies of Menerba in dogs and rats required by the FDA prior to Phase 3 initiation.

"We expect the animal toxicological studies will be completed at the same time as the human tolerability study," said Dr. Isaac Cohen, Bionovo's Chairman and Chief Executive Officer. "An interim report shows no adverse effects observed at the highest feasible dose tested."

  • The Company has completed the construction and validation of its drug substance manufacturing facility in Hayward, California, and is commencing the manufacture of clinical material for the planned Phase 3 trial of Menerba. This facility replaces a contract manufacturer that was unable to meet the Company's requirements for time, cost and quality.

"By identifying and securing an idle drug manufacturing facility with appropriate infrastructure, we will be able to shorten our manufacturing runtime, reduce our manufacturing cost, and enhance the quality of the product," said Tom Chesterman, Bionovo's Chief Financial Officer.

First Quarter Results

Total operating expenses for the three months ending March 31, 2011 were $4.9 million compared to $4.7 million for the same period in 2010. Total operating expenses for the first quarter included costs associated with initiating the Menerba tolerability clinical trial. The Company expects operating expenses to increase in the second quarter as it continues the tolerability testing for Menerba.

The Company reported a net loss for the three months ended March 31, 2011 of $1.7 million, or $0.04 per share, compared with a net loss of $4.7 million, or $0.22 per share, for the same period in 2010.  The decrease in net loss is due to the change in fair market value of the Company's warrant liability of $3.1 million included in non-operating income for the three months ended March 31, 2011.

The Company ended the quarter with $23.1 million in cash, cash equivalents and short term investments, and began the quarter with $2.6 million, a difference of $20.5 million. The cash balance at the end of the quarter reflects the proceeds of the Company's February 2011 public offering offset by operating expenses and capital expenditures to support the Menerba manufacturing facility in Hayward, California.

Conference Call

Bionovo will conduct a conference call and webcast to review the Company's financial results and plans for 2011, today at 2 p.m., Pacific Time. Interested parties can access the call by dialing 800-747-9564, or can listen via a live audio only webcast, which can be found at http://bionovo.com/investors/events. A replay of the call will be available by dialing 800-633-8625 (replay code: 21523134 #) or via audio webcast at http://bionovo.com/investors/events.

About Bionovo, Inc.

Bionovo, Inc. is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit: http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

Financial Tables on Following Pages

Bionovo, Inc.

(A Development Stage Company)

Condensed Consolidated Statements of Operations

(Unaudited, in thousands, except per share data)



For the Three Months Ended
March 31,


Accumulated from
February 1, 2002
(Date of inception)
to March 31,


2011


2010


2011













Revenue

$                    65


$                       -


$                   1,858







Operating expenses:






Research and development

3,883


3,806


58,230

General and administrative

994


852


22,123

Merger cost

-


-


1,964

Total operating expenses

4,877


4,658


82,317







Loss from operations

(4,812)


(4,658)


(80,459)







Other income (expense):






Change in fair value of warrant liability

3,122


-


3,859

Interest income

9


8


2,100

Interest expense

(29)


(14)


(550)

Other expense, net

-


3


(206)

Total other income (expense)

3,102


(3)


5,203







Net loss

$              (1,710)


$              (4,661)


$               (75,256)

Basic and diluted net loss per common share

$                (0.04)


$                (0.22)


$                   (6.39)







Shares used in computing basic and diluted
   net loss per share

43,550


21,509


11,786









Bionovo, Inc.

(A Development Stage Company)

Consolidated Balance Sheets

(in thousands, except share data)



March 31,
2011


December 31,
2010


(unaudited)



ASSETS

Current assets:




Cash and cash equivalents

$                   16,718


$                     2,638

Short-term investments

6,340


-

Receivables

76


49

Prepaid expenses

795


973

Other current assets

406


396

Total current assets

24,335


4,056

Property and equipment, net

12,116


6,647

Patents pending, net

1,465


1,259

Other assets

1,265


1,020

Total assets

$                   39,181


$                   12,982





LIABILITIES AND SHAREHOLDERS’ EQUITY


Current liabilities:




Accounts payable

$                        613


$                        655

Accrued compensation and benefits

537


901

Current portion of capital lease obligations

989


1,055

Current portion of notes payable

27


40

Warrant liability

8,912


1,843

Other current liabilities

5,309


970

Total current liabilities

16,387


5,464

Non-current portion of capital lease obligations

583


836

Non-current portion of notes payable

79


81

Total liabilities

17,049


6,381





Commitments and contingencies








Shareholders’ equity:




Preferred stock, $0.0001 par value; 10,000,000 shares authorized; none issued and outstanding

-


-

Common stock $0.0001 par value, 340,000,000 shares authorized, 54,561,312 and 24,530,112 shares outstanding at March 31, 2011 and December 31, 2010, respectively

5


2

Additional paid-in capital

97,383


80,145

Accumulated other comprehensive income (loss)

-


-

Accumulated deficit

(75,256)


(73,546)

Total shareholders’ equity

22,132


6,601

Total liabilities and shareholders’ equity

$                   39,181


$                   12,982





* The balance sheet at December 31, 2010 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.



SOURCE Bionovo, Inc.